Myelodysplastic syndrome treatment with danazol and cis‐retinoic acid

Louis Letendre; Ralph Levitt; Robert V. Pierre; Georgene Schroeder; James A. Krook; James E. Mailliard; Roscoe F. Morton; Loren K. Tschetter

doi:10.1002/ajh.2830480405

Myelodysplastic syndrome treatment with danazol and cis‐retinoic acid

Louis Letendre, Ralph Levitt, Robert V. Pierre, Georgene Schroeder, James A. Krook, James E. Mailliard, Roscoe F. Morton, Loren K. Tschetter

In: American Journal of Hematology · 1995 · vol. 48(4) , pp. 233–236 · doi:10.1002/ajh.2830480405 · PMID:7717370 · W2102299347

article OA: closed CC0 ⤵ 5 in-corpus citations

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by qwen3.7-flash, 2026-08-15 ⓘ

This study evaluated danazol and cis-retinoic acid in myelodysplastic syndrome, finding minimal activity and concluding that neither compound is effective enough to justify their use for treating the condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We prospectively treated 46 patients with favorable myelodysplastic syndrome classified as refractory anemia (RA), refractory cytopenia (RC), or refractory anemia with ringed sideroblasts (RARS). These patients received one of two schedules of 13-Cis-Retinoic Acid (low dose 80 mg daily for 6 months vs. high dose 200 mg po daily for 3 months), or Danazol (800 mg po daily for 3 months), and were crossed over to the alternative drug in the absence of response or at progression. Using strict criteria of response we found little objective evidence of activity for either compound. Only two minor responses were seen among 22 patients treated with low dose 13-CRA, 1 response among 20 cases that received high dose 13-CRA, and 1 partial response and 1 minor response to Danazol among 34 cases. Neither 13-Cis-Retinoic Acid nor Danazol appear active enough in patients with favorable myelodysplastic syndrome to justify their use.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Danazol treatment of myelodysplastic syndromes 2008

Cited by (2)

References (20)

Danazol treatment of myelodysplastic syndromes via openalex
doi:10.1182/blood.v71.3.703.703 via openalex
doi:10.1093/jnci/60.5.1035 via openalex
doi:10.1016/0092-8674(78)90008-9 via openalex
W2412335873 via openalex
W2415995382 via openalex
W2464011746 via openalex
doi:10.7326/0003-4819-103-1-58 via openalex
doi:10.1111/j.1365-2141.1976.tb03563.x via openalex
doi:10.1073/pnas.77.5.2936 via openalex
doi:10.1016/s0140-6736(87)92796-6 via openalex
doi:10.1111/j.1365-2141.1982.tb08475.x via openalex
doi:10.1016/s0140-6736(59)91835-5 via openalex
doi:10.1111/j.1600-0609.1986.tb00855.x via openalex
doi:10.1200/jco.1986.4.4.589 via openalex
doi:10.1111/j.1600-0609.1986.tb00854.x via openalex
doi:10.7326/0003-4819-100-5-689 via openalex
doi:10.1002/1097-0142(19830701)52:1<83::aid-cncr2820520117>3.0.co;2-9 via openalex
W1575302432 via openalex
doi:10.1111/j.1365-2141.1985.tb07329.x via openalex

Cited by (2)

Source provenance

openalex: last seen: 2026-05-11T05:56:47.744056+00:00
unpaywall: last seen: 2026-09-21T07:16:15.697306+00:00

License: CC0 · commercial use OK

[1] Danazol treatment of myelodysplastic syndromes 2008